Oncology
1 drug is in development for Clear Cell Renal Cell Carcinoma (ccRCC).
- Companies
- 1
- Clinical trials
- 6
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Clear Cell Renal Cell Carcinoma (ccRCC) pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| darlifarnib | Kura Oncology, Inc. (KURA) |
About this indication
Clear Cell Renal Cell Carcinoma (ccRCC) context
Oncology·MeSH: Carcinoma, Renal Cell (D002292)
Narrower concept of MeSH descriptor Renal Cell Carcinoma
Prevalence
48.0 / 100K
Incidence
15.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Clear Cell Renal Cell Carcinoma (ccRCC)?
BioSniper tracks 1 drug in development for Clear Cell Renal Cell Carcinoma (ccRCC) across 1 company.
How many clinical trials target Clear Cell Renal Cell Carcinoma (ccRCC)?
There are 6 clinical trials targeting Clear Cell Renal Cell Carcinoma (ccRCC) tracked by BioSniper.
What is the prevalence of Clear Cell Renal Cell Carcinoma (ccRCC)?
The estimated prevalence of Clear Cell Renal Cell Carcinoma (ccRCC) is approximately 48.0 per 100,000 population.